The role of Anti-PD-1/PD-L1 monotherapy as first-line treatment of metastatic NSCLC without targetable mutations and PD-L1 TPS 1–49%
Authors:
- Arpeet T. ShahASArpeet T. Shah
- Joel W. NealJNJoel W. Neal
Open Access
- 1 March 2021
- journal article
- research article
- Published by AME Publishing Company in Precision Cancer Medicine
- Vol. 4, 9